Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 5-16

  Oh, William K ^a,b   Mcdermott, David ^c   Porta, Camillo ^d   Levy, Antonin ^e   Elaidi, Reza ^f   Scotte, Florian ^f   Hawkins, Robert ^g   Castellano, Daniel ^h   Bellmunt, Joaquim ⁱ   Rha, Sun Young ^j   Sun, Jong Mu ^k   Nathan, Paul ^l   Feinberg, Bruce A ^m   Scott, Jeffrey ^m   Mcdermott, Ray ⁿ   Ahn, Jin Hee ^o   Wagstaff, John ^p   Chang, Yen Hwa ^q   Ou, Yen Chuan ^r   Donnellan, Paul ^s   Huang, Chao Yuan ^t   Mccaffrey, John ^u   Chiang, Po Hui ^v   Chuang, Cheng Keng ^v   Korves, Caroline ^w   Neary, Maureen P ^x   Diaz, Jose R ^x   Mehmud, Faisal ^x   Duh, Mei Sheng ^w   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j Yonsei University College of Medicine   (South Korea)

^k Samsung Medical Center   (South Korea)

^l MOUNT VERNON CANCER CENTRE   (United Kingdom)

^m P4 Healthcare   (United States)

ⁿ ADELAIDE AND MEATH HOSPITAL   (Ireland)

^o Asan Medical Center   (South Korea)

^p SINGLETON HOSPITAL   (United Kingdom)

^q TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^r TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^s UNIVERSITY HOSPITAL GALWAY   (Ireland)

^t NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^u MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^v CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^w ANALYSIS GROUP   (United States)

^x GLAXOSMITHKLINE   (United States)

more..

Author keywords

Angiogenesis inhibitors; Dose reduction; Interruption; Renal cell carcinoma; Safety; Treatment patterns

Indexed keywords

BEVACIZUMAB; INTERFERON; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASIA; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CHILL; CLINICAL PRACTICE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; EUROPE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MOUTH PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; PROTEINURIA; RASH; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIA; CARCINOMA, RENAL CELL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; TREATMENT OUTCOME; UNITED STATES;

EID: 84891943861     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2181     Document Type: Article

References (25)

1. Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
2. Gitlitz BJ and Figlin RA: Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 30: 589-600, 2003.
3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540, 1999.
4. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
5. Escudier BE, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318, 2009.
6. Escudier BE, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alpha-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 370: 2103-2111, 2007.
7. Gore ME, Szczylik C, Porta C, et al: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10: 757-763, 2009.
8. Stadler WM, Figlin RA, McDermott DF, et al: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116: 1272-1280, 2010.
9. Food and Drug Administration. Available at http://www.accessdata.fda.gov/ drugsatfda-docs/appletter/2005/021923ltr.pdf. Accessed December 19, 2011.
10. Bayer and Onyx press release: 'Nexavar approved by European Commission for Treatment of Advanced Kidney Cancer'. July 24, 2006.
11. Zhang H, Dong B, Lu JJ, et al: Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9: 249, 2009.
12. National Cancer Institute. Available at: http://www.cancer.gov/ cancertopics/druginfo/fda-sunitinib-malate. Accessed December 19, 2011.
13. Pfizer press release: 'Pfizer's Sutent® is Granted Full Marketing Authorization for First-Line Use in Advanced Kidney Cancer in European Union'. January 18, 2007.
14. Hong MH, Kim HS, Kim C, et al: Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41: 67-72, 2009.
15. Hwang E, Lee HJ, Sul CK and Lim JS: Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single institution experience. Korean J Urol 51: 450-455, 2010.
16. Ansari J, Fatima A, Fernando K, Collins S, James ND and Porfiri E: Sunitinib in patients with metastatic renal cell carcinoma: Birmigham experience. Oncol Rep 24: 507-510, 2010.
17. Yoo C, Kim JE, Lee JE, Ahn JH, Lee DH, Lee JS, et al: The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40: 980-985, 2010.
18. Ueda T, Imamura Y, Komaru A, et al: Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Int J Urol 17: 811-816, 2010.
19. Porta C, Paglino C, Imarisio I, et al: Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 11: 105, 2011.
20. Feinberg BA, Jolly P, Wang S, et al: Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 29: 786-794, 2012.
21. Choueiri TK, Duh MS, Clement J, et al: Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice based on medical chart review. BJU Int 105: 1247-1254, 2010.
22. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ docs/ctcaev3.pdf. Accessed: November, 2011.
23. Houk BE, Bello CL, Kang D, et al: A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15: 2497-2506, 2009.
24. Escudier B, Bellmunt J, Negrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144-2150, 2010.
25. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. Clin Oncol 28: 2137-2143, 2010.